Inhalation Sciences subsidiary Ziccum has been awarded a grant of 500,000 SEK (~ €48,600) by the EU’s Horizon 2020 research and innovation project for scale up of its LaminarPace spray drying technology, the company said.
A small scale version of LaminarPace is currently in use for creation of dry powder formulations of drugs, vaccines, and biologics. According to the company, the Phase 1 grant will fund a feasibility study for a larger aseptic version of LaminarPace for commercial-scale GMP manufacturing.
Ziccum CEO Göran Conradson said, “We’re well aware of how tough competition is for this funding, and how extensively applications are reviewed and evaluated. All projects selected in Horizon 2020 are seen as ground-breaking in their own way. We’re really proud and happy to be chosen.”
The company, which was spun off from Inhalation Sciences in 2017, also said that it has plans for an IPO in the fourth quarter of 2018.
Read the Ziccum press release.
